Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tolDCcitpep
- Development stage
- Phase 2
- Lead developer
- Newcastle University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal, Intraarticular
01
Overview
tolDCcitpep is an investigational autologous cell-based immunotherapy developed by Newcastle University and the Newcastle upon Tyne Hospitals NHS Foundation Trust for the treatment of rheumatoid arthritis (RA). It is an advanced therapy medicinal product (ATMP) consisting of monocyte-derived tolerogenic dendritic cells (TolDC) that are pulsed with a cocktail of synthetic citrullinated peptides representing disease-relevant autoantigens. The therapy is designed to restore immune tolerance by presenting these citrullinated antigens to autoreactive T cells in a non-inflammatory context, thereby suppressing the autoimmune response characteristic of ACPA-positive RA. It is currently being evaluated in the Phase IIa AuToDeCRA-2 trial, which compares various administration routes including intradermal, intra-articular, and intranodal delivery in patients with nil-to-moderate disease activity.
- Other names
- autologous tolerogenic dendritic cells pulsed with citrullinated peptides
02
Targets
Autoreactive citrullinated peptide-specific CD4+ T lymphocyte (Cit-specific CD4+ T cell)CD28 (Cluster of Differentiation 28)Citrullinated peptide–Major Histocompatibility Complex class II complexPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tolDCcitpep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tolDCcitpep.